{"disease":{"id":"mss-pmmr","name":"mss pmmr"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04483219","title":"Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"China Medical University, China","has_results":false},{"nct_id":"NCT06936488","title":"A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR Advanced Colorectal Cancer","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":35,"lead_sponsor_name":"Huai'an First People's Hospital","has_results":false},{"nct_id":"NCT07156682","title":"QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT06513624","title":"ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"National University Hospital, Singapore","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}